Shares of Zealand Pharma A/S (NASDAQ:ZEAL) have received a consensus broker rating score of 1.83 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Zealand Pharma A/S’s rating score has declined by 22% from three months ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a 12 month consensus target price of $27.33 for the company and are forecasting that the company will post ($0.49) earnings per share for the current quarter, according to Zacks. Zacks has also given Zealand Pharma A/S an industry rank of 102 out of 265 based on the ratings given to its competitors.

A number of equities analysts recently weighed in on the company. Morgan Stanley assumed coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued an “overweight” rating and a $28.00 price target on the stock. Guggenheim assumed coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $28.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $26.00 price target on shares of Zealand Pharma A/S in a research note on Monday, October 16th. Goldman Sachs Group assumed coverage on Zealand Pharma A/S in a research note on Wednesday, September 27th. They issued a “buy” rating on the stock. Finally, Zacks Investment Research raised Zealand Pharma A/S from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Wednesday, November 15th.

Shares of Zealand Pharma A/S (NASDAQ:ZEAL) traded up $0.43 during trading on Tuesday, reaching $14.10. 4,358 shares of the company’s stock traded hands, compared to its average volume of 33,057. Zealand Pharma A/S has a 12-month low of $12.54 and a 12-month high of $20.37.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP purchased a new position in Zealand Pharma A/S in the 3rd quarter worth about $3,185,000. Jane Street Group LLC purchased a new position in Zealand Pharma A/S in the 3rd quarter worth about $386,000. Finally, Royce & Associates LP purchased a new position in Zealand Pharma A/S in the 3rd quarter worth about $1,152,000. 13.33% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/12/01/brokerages-expect-zealand-pharma-as-zeal-to-post-0-49-earnings-per-share.html.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.